schliessen

Filtern

 

Bibliotheken

Cover Image

Longitudinal imaging of Alzheimer pathology using [C-11]PIB, [F-18]FDDNP and [F-18]FDG PET

Purpose [ 11 C]PIB and [ 18 F]FDDNP are PET tracers for in vivo detection of the neuropathology underlying Alzheimer’s disease (AD). [ 18 F]FDG is a glucose analogue and its uptake reflects metabolic activity. The purpose of this study was to examine longitudinal changes in these tracers in patients... Full description

Journal Title: European journal of nuclear medicine and molecular imaging 2012, Vol.39 (6), p.990-1000
Main Author: Ossenkoppele, R
Other Authors: Tolboom, N , Foster-Dingley, J.C , Aiaanse, S.F , Boellaard, R , Yaqub, M.M , Windhorst, A.D , Barkhof, F , Lammertsma, A.A , Scheltens, P , van der Flier, W.M , van Berckel, B.N.M
Format: Electronic Article Electronic Article
Language: English
Subjects:
Aged
Alzheimer Disease - diagnostic imaging
Alzheimer Disease - pathology
Alzheimer's disease
Alzheimers disease
Amyloid
Aniline Compounds
Benzothiazoles
Cardiology
Case-Control Studies
Cognitive ability
Cognitive Dysfunction - diagnostic imaging
Female
Glucose
Humans
Imaging
Longitudinal Studies
Male
Medicine
Medicine & Public Health
Metabolic disorders
Middle Aged
Neurodegenerative diseases
Neuropathology
Nitriles
Nuclear Medicine
Oncology
Original Article
Orthopedics
Pathology
Positron emission tomography
Positron-Emission Tomography - methods
Radiology
Stilbenes
Temporal lobe
Time Factors
Tomography
Tracers
Publisher: Berlin/Heidelberg: Springer-Verlag
ID: ISSN: 1619-7070
Link: https://www.ncbi.nlm.nih.gov/pubmed/22441582
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1017979032
title: Longitudinal imaging of Alzheimer pathology using [C-11]PIB, [F-18]FDDNP and [F-18]FDG PET
format: Article
creator:
  • Ossenkoppele, R
  • Tolboom, N
  • Foster-Dingley, J.C
  • Aiaanse, S.F
  • Boellaard, R
  • Yaqub, M.M
  • Windhorst, A.D
  • Barkhof, F
  • Lammertsma, A.A
  • Scheltens, P
  • van der Flier, W.M
  • van Berckel, B.N.M
subjects:
  • Aged
  • Alzheimer Disease - diagnostic imaging
  • Alzheimer Disease - pathology
  • Alzheimer's disease
  • Alzheimers disease
  • Amyloid
  • Aniline Compounds
  • Benzothiazoles
  • Cardiology
  • Case-Control Studies
  • Cognitive ability
  • Cognitive Dysfunction - diagnostic imaging
  • Female
  • Glucose
  • Humans
  • Imaging
  • Longitudinal Studies
  • Male
  • Medicine
  • Medicine & Public Health
  • Metabolic disorders
  • Middle Aged
  • Neurodegenerative diseases
  • Neuropathology
  • Nitriles
  • Nuclear Medicine
  • Oncology
  • Original Article
  • Orthopedics
  • Pathology
  • Positron emission tomography
  • Positron-Emission Tomography - methods
  • Radiology
  • Stilbenes
  • Temporal lobe
  • Time Factors
  • Tomography
  • Tracers
ispartof: European journal of nuclear medicine and molecular imaging, 2012, Vol.39 (6), p.990-1000
description: Purpose [ 11 C]PIB and [ 18 F]FDDNP are PET tracers for in vivo detection of the neuropathology underlying Alzheimer’s disease (AD). [ 18 F]FDG is a glucose analogue and its uptake reflects metabolic activity. The purpose of this study was to examine longitudinal changes in these tracers in patients with AD or mild cognitive impairment (MCI) and in healthy controls. Methods Longitudinal, paired, dynamic [ 11 C]PIB and [ 18 F]FDDNP (90 min each) and static [ 18 F]FDG (15 min) PET scans were obtained in 11 controls, 12 MCI patients and 8 AD patients. The mean interval between baseline and follow-up was 2.5 years (range 2.0–4.0 years). Parametric [ 11 C]PIB and [ 18 F]FDDNP images of binding potential (BP ND ) and [ 18 F]FDG standardized uptake value ratio (SUVr) images were generated. Results A significant increase in global cortical [ 11 C]PIB BP ND was found in MCI patients, but no changes were observed in AD patients or controls. Subsequent regional analysis revealed that this increase in [ 11 C]PIB BP ND in MCI patients was most prominent in the lateral temporal lobe ( p  
language: eng
source:
identifier: ISSN: 1619-7070
fulltext: no_fulltext
issn:
  • 1619-7070
  • 1619-7089
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.609177
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_cross
recordidTN_cdi_proquest_miscellaneous_1017979032
sourceformatXML
sourcesystemPC
sourcerecordid1017979032
originalsourceidFETCH-LOGICAL-c482t-84c658cf4e6d4abc6a9c0720047a2a229dac78588b89c0466a7644ddec668be10
addsrcrecordideNqNkU9v1DAQxSMEoqXwAbigSFw4EJjxOv5zbLfdUmkFeygXqmI5jpO6ZOPFTiq1nx5vU1aoEoiTPZrfezOal2WvET4gAP8YAUgpC0BSEARSzJ5k-8hQFhyEfLr7c9jLXsR4DYCCCPk82yOEUiwF2c--LX3fumGsXa-73K116_o2901-2N1dWbe2Id_o4cp3vr3Nx7htXswLxMvV2dH7_GJRoLhcHB9_XuW6r3f1ab46OX-ZPWt0F-2rh_cg-7o4OZ9_KpZfTs_mh8vCUEGGQlDDSmEaallNdWWYlgY4AaBcE02IrLXhohSiEqlBGdOcUVrX1jAmKotwkL2bfDfB_xxtHNTaRWO7TvfWj1EhIJdcwoz8D4oJZmWZ0LeP0Gs_hnSke2pGKecoE4UTZYKPMdhGbUI6YrhNkNpmpKaMVMpIbTNSs6R58-A8Vmtb7xS_Q0kAf2Rq3KAH5_shaNf905pMyphM-9aGP5f-u-j7JOp1MC7u9rkZ10Z57dRmDFal-UGr-keqqs6Z-3Wioo1FVhtUDVZG0QorJRmrlQDLLZSNtFDBL1tsymc
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1013447719
display
typearticle
titleLongitudinal imaging of Alzheimer pathology using [C-11]PIB, [F-18]FDDNP and [F-18]FDG PET
creatorOssenkoppele, R ; Tolboom, N ; Foster-Dingley, J.C ; Aiaanse, S.F ; Boellaard, R ; Yaqub, M.M ; Windhorst, A.D ; Barkhof, F ; Lammertsma, A.A ; Scheltens, P ; van der Flier, W.M ; van Berckel, B.N.M
creatorcontribOssenkoppele, R ; Tolboom, N ; Foster-Dingley, J.C ; Aiaanse, S.F ; Boellaard, R ; Yaqub, M.M ; Windhorst, A.D ; Barkhof, F ; Lammertsma, A.A ; Scheltens, P ; van der Flier, W.M ; van Berckel, B.N.M
descriptionPurpose [ 11 C]PIB and [ 18 F]FDDNP are PET tracers for in vivo detection of the neuropathology underlying Alzheimer’s disease (AD). [ 18 F]FDG is a glucose analogue and its uptake reflects metabolic activity. The purpose of this study was to examine longitudinal changes in these tracers in patients with AD or mild cognitive impairment (MCI) and in healthy controls. Methods Longitudinal, paired, dynamic [ 11 C]PIB and [ 18 F]FDDNP (90 min each) and static [ 18 F]FDG (15 min) PET scans were obtained in 11 controls, 12 MCI patients and 8 AD patients. The mean interval between baseline and follow-up was 2.5 years (range 2.0–4.0 years). Parametric [ 11 C]PIB and [ 18 F]FDDNP images of binding potential (BP ND ) and [ 18 F]FDG standardized uptake value ratio (SUVr) images were generated. Results A significant increase in global cortical [ 11 C]PIB BP ND was found in MCI patients, but no changes were observed in AD patients or controls. Subsequent regional analysis revealed that this increase in [ 11 C]PIB BP ND in MCI patients was most prominent in the lateral temporal lobe ( p  < 0.05). For [ 18 F]FDDNP, no changes in global BP ND were found. [ 18 F]FDG uptake was reduced at follow-up in the AD group only, especially in frontal, parietal and lateral temporal lobes (all p  < 0.01). Changes in global [ 11 C]PIB binding (ρ = −0.42, p  < 0.05) and posterior cingulate [ 18 F]FDG uptake (ρ = 0.54, p  < 0.01) were correlated with changes in Mini-Mental-State Examination score over time across groups, whilst changes in [ 18 F]FDDNP binding (ρ = −0.18, p  = 0.35) were not. Conclusion [ 11 C]PIB and [ 18 F]FDG track molecular changes in different stages of AD. We found increased amyloid load in MCI patients and progressive metabolic impairment in AD patients. [ 18 F]FDDNP seems to be less useful for examining disease progression.
identifier
0ISSN: 1619-7070
1EISSN: 1619-7089
2DOI: 10.1007/s00259-012-2102-3
3PMID: 22441582
languageeng
publisherBerlin/Heidelberg: Springer-Verlag
subjectAged ; Alzheimer Disease - diagnostic imaging ; Alzheimer Disease - pathology ; Alzheimer's disease ; Alzheimers disease ; Amyloid ; Aniline Compounds ; Benzothiazoles ; Cardiology ; Case-Control Studies ; Cognitive ability ; Cognitive Dysfunction - diagnostic imaging ; Female ; Glucose ; Humans ; Imaging ; Longitudinal Studies ; Male ; Medicine ; Medicine & Public Health ; Metabolic disorders ; Middle Aged ; Neurodegenerative diseases ; Neuropathology ; Nitriles ; Nuclear Medicine ; Oncology ; Original Article ; Orthopedics ; Pathology ; Positron emission tomography ; Positron-Emission Tomography - methods ; Radiology ; Stilbenes ; Temporal lobe ; Time Factors ; Tomography ; Tracers
ispartofEuropean journal of nuclear medicine and molecular imaging, 2012, Vol.39 (6), p.990-1000
rights
0info:eu-repo/semantics/closedAccess
1Springer-Verlag 2012
lds50peer_reviewed
citedbyFETCH-LOGICAL-c482t-84c658cf4e6d4abc6a9c0720047a2a229dac78588b89c0466a7644ddec668be10
citesFETCH-LOGICAL-c482t-84c658cf4e6d4abc6a9c0720047a2a229dac78588b89c0466a7644ddec668be10
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22441582$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Ossenkoppele, R
1Tolboom, N
2Foster-Dingley, J.C
3Aiaanse, S.F
4Boellaard, R
5Yaqub, M.M
6Windhorst, A.D
7Barkhof, F
8Lammertsma, A.A
9Scheltens, P
10van der Flier, W.M
11van Berckel, B.N.M
title
0Longitudinal imaging of Alzheimer pathology using [C-11]PIB, [F-18]FDDNP and [F-18]FDG PET
1European journal of nuclear medicine and molecular imaging
addtitle
0Eur J Nucl Med Mol Imaging
1Eur J Nucl Med Mol Imaging
descriptionPurpose [ 11 C]PIB and [ 18 F]FDDNP are PET tracers for in vivo detection of the neuropathology underlying Alzheimer’s disease (AD). [ 18 F]FDG is a glucose analogue and its uptake reflects metabolic activity. The purpose of this study was to examine longitudinal changes in these tracers in patients with AD or mild cognitive impairment (MCI) and in healthy controls. Methods Longitudinal, paired, dynamic [ 11 C]PIB and [ 18 F]FDDNP (90 min each) and static [ 18 F]FDG (15 min) PET scans were obtained in 11 controls, 12 MCI patients and 8 AD patients. The mean interval between baseline and follow-up was 2.5 years (range 2.0–4.0 years). Parametric [ 11 C]PIB and [ 18 F]FDDNP images of binding potential (BP ND ) and [ 18 F]FDG standardized uptake value ratio (SUVr) images were generated. Results A significant increase in global cortical [ 11 C]PIB BP ND was found in MCI patients, but no changes were observed in AD patients or controls. Subsequent regional analysis revealed that this increase in [ 11 C]PIB BP ND in MCI patients was most prominent in the lateral temporal lobe ( p  < 0.05). For [ 18 F]FDDNP, no changes in global BP ND were found. [ 18 F]FDG uptake was reduced at follow-up in the AD group only, especially in frontal, parietal and lateral temporal lobes (all p  < 0.01). Changes in global [ 11 C]PIB binding (ρ = −0.42, p  < 0.05) and posterior cingulate [ 18 F]FDG uptake (ρ = 0.54, p  < 0.01) were correlated with changes in Mini-Mental-State Examination score over time across groups, whilst changes in [ 18 F]FDDNP binding (ρ = −0.18, p  = 0.35) were not. Conclusion [ 11 C]PIB and [ 18 F]FDG track molecular changes in different stages of AD. We found increased amyloid load in MCI patients and progressive metabolic impairment in AD patients. [ 18 F]FDDNP seems to be less useful for examining disease progression.
subject
0Aged
1Alzheimer Disease - diagnostic imaging
2Alzheimer Disease - pathology
3Alzheimer's disease
4Alzheimers disease
5Amyloid
6Aniline Compounds
7Benzothiazoles
8Cardiology
9Case-Control Studies
10Cognitive ability
11Cognitive Dysfunction - diagnostic imaging
12Female
13Glucose
14Humans
15Imaging
16Longitudinal Studies
17Male
18Medicine
19Medicine & Public Health
20Metabolic disorders
21Middle Aged
22Neurodegenerative diseases
23Neuropathology
24Nitriles
25Nuclear Medicine
26Oncology
27Original Article
28Orthopedics
29Pathology
30Positron emission tomography
31Positron-Emission Tomography - methods
32Radiology
33Stilbenes
34Temporal lobe
35Time Factors
36Tomography
37Tracers
issn
01619-7070
11619-7089
fulltextfalse
rsrctypearticle
creationdate2012
recordtypearticle
recordideNqNkU9v1DAQxSMEoqXwAbigSFw4EJjxOv5zbLfdUmkFeygXqmI5jpO6ZOPFTiq1nx5vU1aoEoiTPZrfezOal2WvET4gAP8YAUgpC0BSEARSzJ5k-8hQFhyEfLr7c9jLXsR4DYCCCPk82yOEUiwF2c--LX3fumGsXa-73K116_o2901-2N1dWbe2Id_o4cp3vr3Nx7htXswLxMvV2dH7_GJRoLhcHB9_XuW6r3f1ab46OX-ZPWt0F-2rh_cg-7o4OZ9_KpZfTs_mh8vCUEGGQlDDSmEaallNdWWYlgY4AaBcE02IrLXhohSiEqlBGdOcUVrX1jAmKotwkL2bfDfB_xxtHNTaRWO7TvfWj1EhIJdcwoz8D4oJZmWZ0LeP0Gs_hnSke2pGKecoE4UTZYKPMdhGbUI6YrhNkNpmpKaMVMpIbTNSs6R58-A8Vmtb7xS_Q0kAf2Rq3KAH5_shaNf905pMyphM-9aGP5f-u-j7JOp1MC7u9rkZ10Z57dRmDFal-UGr-keqqs6Z-3Wioo1FVhtUDVZG0QorJRmrlQDLLZSNtFDBL1tsymc
startdate2012
enddate2012
creator
0Ossenkoppele, R
1Tolboom, N
2Foster-Dingley, J.C
3Aiaanse, S.F
4Boellaard, R
5Yaqub, M.M
6Windhorst, A.D
7Barkhof, F
8Lammertsma, A.A
9Scheltens, P
10van der Flier, W.M
11van Berckel, B.N.M
general
0Springer-Verlag
1Springer Nature B.V
scope
05DI
15DJ
2QVL
3CGR
4CUY
5CVF
6ECM
7EIF
8NPM
9AAYXX
10CITATION
113V.
127RV
137TK
147X7
157XB
1688E
178AO
188FE
198FG
208FH
218FI
228FJ
238FK
24ABUWG
25ARAPS
26AZQEC
27BBNVY
28BENPR
29BGLVJ
30BHPHI
31DWQXO
32FYUFA
33GHDGH
34GNUQQ
35HCIFZ
36K9.
37KB0
38LK8
39M0S
40M1P
41M7P
42NAPCQ
43P5Z
44P62
45PQEST
46PQQKQ
47PQUKI
48PRINS
497X8
507QO
518FD
52FR3
53P64
sort
creationdate2012
titleLongitudinal imaging of Alzheimer pathology using [C-11]PIB, [F-18]FDDNP and [F-18]FDG PET
authorOssenkoppele, R ; Tolboom, N ; Foster-Dingley, J.C ; Aiaanse, S.F ; Boellaard, R ; Yaqub, M.M ; Windhorst, A.D ; Barkhof, F ; Lammertsma, A.A ; Scheltens, P ; van der Flier, W.M ; van Berckel, B.N.M
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c482t-84c658cf4e6d4abc6a9c0720047a2a229dac78588b89c0466a7644ddec668be10
rsrctypearticles
prefilterarticles
languageeng
creationdate2012
topic
0Aged
1Alzheimer Disease - diagnostic imaging
2Alzheimer Disease - pathology
3Alzheimer's disease
4Alzheimers disease
5Amyloid
6Aniline Compounds
7Benzothiazoles
8Cardiology
9Case-Control Studies
10Cognitive ability
11Cognitive Dysfunction - diagnostic imaging
12Female
13Glucose
14Humans
15Imaging
16Longitudinal Studies
17Male
18Medicine
19Medicine & Public Health
20Metabolic disorders
21Middle Aged
22Neurodegenerative diseases
23Neuropathology
24Nitriles
25Nuclear Medicine
26Oncology
27Original Article
28Orthopedics
29Pathology
30Positron emission tomography
31Positron-Emission Tomography - methods
32Radiology
33Stilbenes
34Temporal lobe
35Time Factors
36Tomography
37Tracers
toplevelpeer_reviewed
creatorcontrib
0Ossenkoppele, R
1Tolboom, N
2Foster-Dingley, J.C
3Aiaanse, S.F
4Boellaard, R
5Yaqub, M.M
6Windhorst, A.D
7Barkhof, F
8Lammertsma, A.A
9Scheltens, P
10van der Flier, W.M
11van Berckel, B.N.M
collection
0NARCIS
1NARCIS: Datasets
2NARCIS:Publications
3Medline
4MEDLINE
5MEDLINE (Ovid)
6MEDLINE
7MEDLINE
8PubMed
9CrossRef
10ProQuest Central (Corporate)
11Nursing & Allied Health Database
12Neurosciences Abstracts
13Health & Medical Collection
14ProQuest Central (purchase pre-March 2016)
15Medical Database (Alumni Edition)
16ProQuest Pharma Collection
17ProQuest SciTech Collection
18ProQuest Technology Collection
19ProQuest Natural Science Collection
20Hospital Premium Collection
21Hospital Premium Collection (Alumni Edition)
22ProQuest Central (Alumni) (purchase pre-March 2016)
23ProQuest Central (Alumni Edition)
24Advanced Technologies & Aerospace Collection
25ProQuest Central Essentials
26Biological Science Collection
27ProQuest Central
28Technology Collection
29Natural Science Collection
30ProQuest Central Korea
31Health Research Premium Collection
32Health Research Premium Collection (Alumni)
33ProQuest Central Student
34SciTech Premium Collection
35ProQuest Health & Medical Complete (Alumni)
36Nursing & Allied Health Database (Alumni Edition)
37ProQuest Biological Science Collection
38Health & Medical Collection (Alumni Edition)
39Medical Database
40Biological Science Database
41Nursing & Allied Health Premium
42Advanced Technologies & Aerospace Database
43ProQuest Advanced Technologies & Aerospace Collection
44ProQuest One Academic Eastern Edition
45ProQuest One Academic
46ProQuest One Academic UKI Edition
47ProQuest Central China
48MEDLINE - Academic
49Biotechnology Research Abstracts
50Technology Research Database
51Engineering Research Database
52Biotechnology and BioEngineering Abstracts
jtitleEuropean journal of nuclear medicine and molecular imaging
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Ossenkoppele, R
1Tolboom, N
2Foster-Dingley, J.C
3Aiaanse, S.F
4Boellaard, R
5Yaqub, M.M
6Windhorst, A.D
7Barkhof, F
8Lammertsma, A.A
9Scheltens, P
10van der Flier, W.M
11van Berckel, B.N.M
formatjournal
genrearticle
ristypeJOUR
atitleLongitudinal imaging of Alzheimer pathology using [C-11]PIB, [F-18]FDDNP and [F-18]FDG PET
jtitleEuropean journal of nuclear medicine and molecular imaging
stitleEur J Nucl Med Mol Imaging
addtitleEur J Nucl Med Mol Imaging
date2012
risdate2012
volume39
issue6
spage990
epage1000
pages990-1000
issn1619-7070
eissn1619-7089
abstractPurpose [ 11 C]PIB and [ 18 F]FDDNP are PET tracers for in vivo detection of the neuropathology underlying Alzheimer’s disease (AD). [ 18 F]FDG is a glucose analogue and its uptake reflects metabolic activity. The purpose of this study was to examine longitudinal changes in these tracers in patients with AD or mild cognitive impairment (MCI) and in healthy controls. Methods Longitudinal, paired, dynamic [ 11 C]PIB and [ 18 F]FDDNP (90 min each) and static [ 18 F]FDG (15 min) PET scans were obtained in 11 controls, 12 MCI patients and 8 AD patients. The mean interval between baseline and follow-up was 2.5 years (range 2.0–4.0 years). Parametric [ 11 C]PIB and [ 18 F]FDDNP images of binding potential (BP ND ) and [ 18 F]FDG standardized uptake value ratio (SUVr) images were generated. Results A significant increase in global cortical [ 11 C]PIB BP ND was found in MCI patients, but no changes were observed in AD patients or controls. Subsequent regional analysis revealed that this increase in [ 11 C]PIB BP ND in MCI patients was most prominent in the lateral temporal lobe ( p  < 0.05). For [ 18 F]FDDNP, no changes in global BP ND were found. [ 18 F]FDG uptake was reduced at follow-up in the AD group only, especially in frontal, parietal and lateral temporal lobes (all p  < 0.01). Changes in global [ 11 C]PIB binding (ρ = −0.42, p  < 0.05) and posterior cingulate [ 18 F]FDG uptake (ρ = 0.54, p  < 0.01) were correlated with changes in Mini-Mental-State Examination score over time across groups, whilst changes in [ 18 F]FDDNP binding (ρ = −0.18, p  = 0.35) were not. Conclusion [ 11 C]PIB and [ 18 F]FDG track molecular changes in different stages of AD. We found increased amyloid load in MCI patients and progressive metabolic impairment in AD patients. [ 18 F]FDDNP seems to be less useful for examining disease progression.
copBerlin/Heidelberg
pubSpringer-Verlag
pmid22441582
doi10.1007/s00259-012-2102-3